Non-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo
. GPR55 and weak CB1
values are 0.445 and 3.35 μ
receptor inverse agonist and inhibitor of anandamide uptake (IC50
= 27.5 μ
M). Also a weak agonist at VR1 vanilloid receptors (EC50
= 3.5 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The orphan receptor GPR55 is a novel cannabinoid receptor.
Ryberg et al.
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
Costa et al.
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas et al.
Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet et al.
Life Sci., 1998;63:PL1
The citations listed below are publications that use Tocris products. Selected citations for (-)-Cannabidiol include:
Showing Results 1 - 2 of 2